<i>MTNR1B</i> polymorphisms with <i>CDKN2A</i> and <i>MGMT</i> methylation status are associated with poor prognosis of colorectal cancer in Taiwan
Chia‐Cheng Lee, Yu‐Cheng Kuo, Je‐Ming Hu, Pi-Kai Chang, Chien‐An Sun, Tsan Yang, Chuan-Wang Li, Chaoyang Chen, Fu‐Huang Lin, Chih‐Hsiung Hsu, Yu‐Ching Chou
Abstract
BACKGROUND: Identifying novel colorectal cancer (CRC) prognostic biomarkers is crucial to helping clinicians make appropriate therapy decisions. Melatonin plays a major role in managing the circadian rhythm and exerts oncostatic effects on different kinds of tumours. AIM: single-nucleotide polymorphism (SNPs) combined with gene hypermethylation and CRC prognosis. METHODS: SNPs and CRC 5-year overall survival (OS) was assessed by calculating hazard ratios with 95%CIs. RESULTS: gene methylation status could be used to predict shorter CRC survival. CONCLUSION: The novel genetic biomarkers combined with epigenetic biomarkers may be predictive tool for CRC prognosis and thus could be used to individualise treatment for patients with CRC.